Global Blood Therapeutics is a clinical-stage biopharmaceutical company determined to discover, develop and deliver treatments that provide hope to underserved patient communities. Co.'s primary product candidate is voxelotor, an oral, once-daily therapy that modulates hemoglobin's affinity for oxygen, which inhibits hemoglobin polymerization in sickle cell disease (SCD). Co. is evaluating voxelotor in adult and adolescent patients with SCD in a Phase 3 clinical trial. Co. is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in adolescent and pediatric patients with SCD in a Phase 2a clinical trial.
GBT — Key Stats (updated Friday, March 27, 10:31 AM)